Share
 
Title
Code
Session Type
Venue
Date Time
Co-Chairs:

This session focuses on the pragmatic issues raised by the development of newer treatments for HIV, HCV, and TB. It provides an overview and a critical analysis of current drug pipelines, the cost implications in resource-limited settings, drug interactions (including medications used to treat other comorbidities), issues of access for key populations, and innovative methods to increase access and epidemic control. It is directed towards clinical practitioners and researchers, programme implementers as well as PLHIV representatives and advocates. At the completion of the session, participants will know of new advances in medications and management of HIV, TB, and hepatitis C and be able to discuss novel programmes that have increased access to new medications in resource-limited settings.

16:30
TUSY1101
Introduction

16:34
TUSY1102
Innovations in HIV treatment: what the future holds
François Venter, University of Witswatersrand, South Africa

16:48
TUSY1103
Innovations in HCV treatment: what the future holds
Jürgen K. Rockstroh, University of Bonn, Germany
Slides

17:02
TUSY1104
Innovations in TB treatment: what the future holds
Padmapriyadarsini Chandrasekaran, National Institute for Research in Tuberculosis (ICMR), India
Slides

17:16
TUSY1105
Innovation in the development of new drugs and creative solutions to ensuring early and enhanced access
Paul Stoffels, Johnson & Johnson, United States
Slides

17:30
TUSY1106
How to make the future of HIV, HCV, and TB treatment happen now
James Packard Love, Knowledge Ecology International (KEI), United States
17:44
TUSY1107
Panel discussion and question and answers

17:58
TUSY1108
Conclusion